Research
The efficacy of intravitreal antivascular endothelial growth factor as primary treatment of retinopathy of prematurity: Experience from a tertiary hospital
Abstract
Background. Retinopathy of prematurity (ROP) is a vasoproliferative disease affecting premature babies and a major cause of blindness in childhood. Appropriate screening and treatment can prevent blindness.
Objective. To report on the efficacy of using antivascular endothelial growth factor (bevacizumab) as first-line therapy in ROP.
Methods. This was a retrospective analysis of patients with ROP treated at St John Eye Hospital, Johannesburg, South Africa, over a 3-year period. Outcome measures were the clinical response to intravitreal bevacizumab (IVB) as well as the economic impact of IVB therapy.
Results. Twenty-three patients were treated for active ROP or type 1 disease, in 44 eyes. Two patients required treatment in one eye only. The mean birth weight of these patients was 1 074 g (range 810 - 1 480). Response to treatment outcome was available for 22 patients (43 eyes). The mean follow-up period was 9 months (range 1 - 18). Forty-one eyes (95.3%) showed complete regression or non-progression of the disease. Two eyes (one eye each in two patients) progressed to advanced disease. There were no short-term adverse events. A cost-effective model showed that IVB treatment was much more economical than laser therapy.
Conclusion. IVB is a safe and effective first-line treatment for ROP and should be considered in resource-limited centres.
Authors' affiliations
H Kana, St John Eye Hospital-Chris Hani Baragwanath Academic Hospital and Department of Ophthalmology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
I Mayet, St John Eye Hospital-Chris Hani Baragwanath Academic Hospital and Department of Ophthalmology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
D Soma, St John Eye Hospital-Chris Hani Baragwanath Academic Hospital and Department of Ophthalmology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
H Dawood Alli, St John Eye Hospital-Chris Hani Baragwanath Academic Hospital and Department of Ophthalmology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
S Biddulph, St John Eye Hospital-Chris Hani Baragwanath Academic Hospital and Department of Ophthalmology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Full Text
PDF (153KB)Keywords
Cite this article
Article History
Date published: 2017-02-27
Article Views
Full text views: 1129
Comments on this article
*Read our policy for posting comments here